Login to Your Account



Other News To Note


Wednesday, November 13, 2013
• Bioasis Technologies Inc., of Vancouver, British Columbia, said new research in animals conducted under its BT2111 program showed that the drug, a conjugate of Herceptin (trastuzumab, Roche AG), not only crosses the blood-brain barrier, but also penetrates the blood-tumor barrier up to 10 times better than Herceptin alone.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription